West Pharmaceutical Services (WST) Common Equity (2009 - 2026)

West Pharmaceutical Services has disclosed Common Equity across 18 years of filings, most recently posting $3.0 billion for Q1 2026.

• Common Equity for Q1 2026 came in at $3.0 billion, up 11.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.0 billion (up 11.45% YoY), and the FY2025 annual result was $3.2 billion, up 18.41% from the prior year.
• Common Equity came in at $3.0 billion for Q1 2026 at West Pharmaceutical Services, down from $3.2 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $3.2 billion in Q4 2025 to a low of $2.3 billion in Q1 2022.
• The 5-year median for Common Equity is $2.7 billion (2023), against an average of $2.7 billion.
• Across the five-year window, Common Equity advanced 27.18% in 2022 and declined 6.9% in 2024, its largest moves.
• West Pharmaceutical Services' Common Equity stood at $2.7 billion in 2022, then climbed by 7.3% to $2.9 billion in 2023, then declined by 6.9% to $2.7 billion in 2024, then rose by 18.41% to $3.2 billion in 2025, then declined by 5.84% to $3.0 billion in 2026.
• The last three Common Equity figures came in at $3.0 billion (Q1 2026), $3.2 billion (Q4 2025), and $3.1 billion (Q3 2025), per Business Quant data.